Comparison of efficacy of pegylated interferon alfa-2a or interferon alfa-2b combination therapy with nucleos（t）ide analogues in HBeAg positive chronic hepatitis B patients
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1927
2Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to pegintefferon alfa-2b for hepatitis B e antigen- positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology, 2010, 52: 1251-1257.
3Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352: 2682-2695.
8Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1927
9van Nunen AB,Janssen HL,Wolters LM,et al.Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?[J].Antiviral Res,2001,52(2):139-146.
10Yeh ML,Peng CY,Dai CY,et al. Pegylated-interferon al- pha therapy for treatment-experienced chronic hepatitis B patients[J]. PLoS One, 2015,10(4) : e0122259.
